Skip to content
Triangle logo TriangleGet started
← Study library

NCT00176930 · REGISTRY CONDITION SEARCH

Stem Cell Transplant for Hematological Malignancy

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
NA
Status at capture
TERMINATED
Registry last update
2021-01-22

The purpose of this study is to develop a standard of care treatment using allogeneic stem cells for patients with cancers of the blood. The protocol was revised to reflect that this study is considered "treatment guidelines", rather than a research study.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants Experiencing Disease-Free Survival at 2 Years Post Transplant

→

outcome · POSTED

Number of Participants Experiencing Disease-Free Survival at 5 Years Post Transplant

→

outcome · POSTED

Number of Participants With Neutrophil Engraftment

→

outcome · POSTED

Number of Participants With Acute Graft-versus-host Disease (GVHD)

→

outcome · POSTED

Number of Participants With Chronic Graft-Versus-Host Disease

→

outcome · POSTED

Number of Participants With Persistence or Relapse of Malignancy at 2 Years Post Transplant

→

outcome · POSTED

Number of Participants With Persistence or Relapse of Malignancy at 5 Years Post Transplant

→

outcome · POSTED

Number of Participants Who Were Alive at 2 Year Post Transplant

→

outcome · POSTED

Number of Participants Who Were Alive at 5 Year Post Transplant

→

outcome · POSTED

Number of Participants Experiencing Engraftment Failure

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Donor will be \<75 years of age and in good health. * Recipients will be \< or = 55 years, will have normal organ function (excluding bone marrow) and will have a Karnofsky activity assessment \> or = 90%. * Recipients with related or unrelated donor matched at the HLA A, B, DRB1 loci, or mismatched related or unrelated (if \< 35 years old) at a single HLA A, B, DRB1 locus. * Recipients will be eligible in one of the following disease categories * Chronic myelogenous leukemia in accelerated phase or in post blast crisis second or greater chronic phase; or in chronic phase but intolerant of or resistant to tyrosine kinase inhibitors. * Acute myelocytic leukemia in first or greater remission, or first, second or third relapse. * Acute lymphocytic leukemia in the 2nd or greater bone marrow remission. * High risk children will be transplanted in first remission if they meet criteria * Myelodysplastic syndrome. * Myeloproliferative Diseases - (i.e. myelofibrosis, chronic myelomonocytic leukemia (CMML)) * Juvenile myelomonocytic leukemia * Chronic lymphocytic leukemia * Advanced non-Hodgkin's (NHL). * Advanced Hodgkin's disease beyond PR2 (\> CR3, \> PR3). * Multiple Myeloma after initial therapy. * Donors and recipients signed informed consent Exclusion Criteria donors and recipients should meet the following test criteria. * required for donors: * anti-HIV, Hepatitis B, surface antigen, anti-HCV, CMV, HSV, EBV serologies, pre-priming. * CBC, platelet count each day of apheresis, day 0 (or 1 or 2 as needed) * required for recipients: * anti-HIV, Hepatitis B, surface antigen, anti-HCV, CMV, HSV, EBV serologies, pre-transplant.
healthy Volunteers
false
maximum Age
55 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Peripheral Blood Stem Cells (PBSC) as a source of transplant
    intervention Names
    1. Biological: Stem Cell Transplant
    2. Drug: Cyclophosphamide
    3. Drug: Busulfan
    label
    PBSC: No TBI
    type
    EXPERIMENTAL
  2. description
    Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Bone Marrow as a source of stem cell transplant
    intervention Names
    1. Biological: Stem Cell Transplant
    2. Drug: Cyclophosphamide
    3. Drug: Busulfan
    label
    Marrow : No TBI
    type
    EXPERIMENTAL
  3. description
    Patients who are not able to receive Total Body Irradiation (TBI) receives cyclophosphamide, Busulfan and Umbilical Cord Blood (UCB) as a source of stem cell transplant
    intervention Names
    1. Biological: Stem Cell Transplant
    2. Drug: Cyclophosphamide
    3. Drug: Busulfan
    label
    UCB : No TBI
    type
    EXPERIMENTAL
  4. description
    Patients who receives Umbilical Cord Blood (UCB) as a source of transplant and who have not had chemotherapy in the prior 3 months receives ATG in addition to cyclophosphamide, Busulfan preparative regimen
    intervention Names
    1. Biological: Stem Cell Transplant
    2. Drug: Cyclophosphamide
    3. Drug: Busulfan
    4. Drug: Equine ATG (ATGAM)
    label
    UCB : No TBI/Bu/Cy/ATG
    type
    EXPERIMENTAL
  5. description
    Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Peripheral blood stem cells as a source of transplant
    intervention Names
    1. Biological: Stem Cell Transplant
    2. Drug: Cyclophosphamide
    3. Radiation: Total Body Irradiation
    label
    PBSC
    type
    EXPERIMENTAL
  6. description
    Patients receiving cyclophosphamide, Total Body Irradiation (TBI) and Bone Marrow as a source of stem cell transplant
    intervention Names
    1. Biological: Stem Cell Transplant
    2. Drug: Cyclophosphamide
    3. Radiation: Total Body Irradiation
    label
    Marrow
    type
    EXPERIMENTAL
  7. description
    Patients receiving cyclophosphamide, Total Body Irradiation (TBI), and Umbilical Cord Blood (UCB) as a source of stem cell transplant
    intervention Names
    1. Biological: Stem Cell Transplant
    2. Drug: Cyclophosphamide
    3. Radiation: Total Body Irradiation
    label
    UCB
    type
    EXPERIMENTAL
  8. description
    Patients receiving cyclophosphamide, Total Body Irradiation (TBI) , CD4+CD25+ and Peripheral Blood Stem Cells (PBSC) as a source of transplant. These patients are co-enrolled on the MT2004-03 trial (NCT00725062)
    intervention Names
    1. Biological: Stem Cell Transplant
    2. Drug: Cyclophosphamide
    3. Radiation: Total Body Irradiation
    4. Biological: CD4+/CD25+ cells
    label
    Co-Enroll From MT0403
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Co-Enroll From MT0403
    2. Marrow
    3. Marrow : No TBI
    4. PBSC
    5. PBSC: No TBI
    6. UCB
    7. UCB : No TBI
    8. UCB : No TBI/Bu/Cy/ATG
    description
    Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover. (Allowable sources of stem cells = related or unrelated bone marrow or peripheral blood, for Busulfan/cyclophosphamide/ATG preparative chemo only, umbilical cord blood is also permitted.)
    name
    Stem Cell Transplant
    other Names
    1. Bone Marrow Transplant.
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Co-Enroll From MT0403
    2. Marrow
    3. Marrow : No TBI
    4. PBSC
    5. PBSC: No TBI
    6. UCB
    7. UCB : No TBI
    8. UCB : No TBI/Bu/Cy/ATG
    description
    60 mg/kg intravenously (IV) Days -6 and -5 or 50 mg/kg/day IV Days -5 through -2.
    name
    Cyclophosphamide
    other Names
    1. Cytoxan
    type
    DRUG
  3. arm Group Labels
    1. Co-Enroll From MT0403
    2. Marrow
    3. PBSC
    4. UCB
    description
    On Day -4, -3, -2, -1 total body irradiation is given twice daily.
    name
    Total Body Irradiation
    other Names
    1. Radiation therapy
    type
    RADIATION
  4. arm Group Labels
    1. Marrow : No TBI
    2. PBSC: No TBI
    3. UCB : No TBI
    4. UCB : No TBI/Bu/Cy/ATG
    description
    When not receiving total body irradiation, administered Days -9 through -6, 0.8 mg/kg/dose by intravenous dosing every 6 hours.
    name
    Busulfan
    other Names
    1. Busulfex
    2. Myleran
    type
    DRUG
  5. arm Group Labels
    1. UCB : No TBI/Bu/Cy/ATG
    description
    UCB recipients who have not had chemotherapy in the preceding 3 months will also receive Equine ATG (ATGAM) 15 mg/kg IV will be administered every 12 hours for 6 doses beginning on day -3 per institutional guidelines
    name
    Equine ATG (ATGAM)
    type
    DRUG
  6. arm Group Labels
    1. Co-Enroll From MT0403
    description
    On days -2, patients will receive CD4+/CD25+ cells intravenously.
    name
    CD4+/CD25+ cells
    type
    BIOLOGICAL
Study design
allocation
NON_RANDOMIZED
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
330
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Disease-Free Survival is the length of time during and after medication or treatment during which the disease being treated (usually cancer) does not get worse. It is sometimes used as a metric to study the health of a person with a disease to try to determine how well a new treatment is working.
    measure
    Number of Participants Experiencing Disease-Free Survival at 2 Years Post Transplant
    time Frame
    2 years
  2. description
    Disease-Free Survival is the length of time during and after medication or treatment during which the disease being treated (usually cancer) does not get worse. It is sometimes used as a metric to study the health of a person with a disease to try to determine how well a new treatment is working.
    measure
    Number of Participants Experiencing Disease-Free Survival at 5 Years Post Transplant
    time Frame
    5 years
secondary Outcomes
  1. description
    Neutrophil engraftment is defined as the first day of three consecutive days where the neutrophil count (absolute neutrophil count) is 500 cells/mm\^3 (0.5 x 10\^9/L) or greater.
    measure
    Number of Participants With Neutrophil Engraftment
    time Frame
    Day 42
  2. description
    Acute Graft-Versus-Host Disease (aGVHD) is a severe short-term complication created by infusion of donor cells into a foreign host. Determine the incidence of grade II-IV acute graft-versus-host disease (GVHD) at day 100 post transplant. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria used for staging. Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.
    measure
    Number of Participants With Acute Graft-versus-host Disease (GVHD)
    time Frame
    Day 100
  3. description
    Chronic Graft-Versus-Host Disease is a severe long-term complication created by infusion of donor cells into a foreign host. Determine the incidence of chronic GVHD 1 year post transplant. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria. Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.
    measure
    Number of Participants With Chronic Graft-Versus-Host Disease
    time Frame
    1 year
  4. description
    Defined as the return of disease after its apparent recovery/cessation. Patients with leukemia and lymphoma involving the BM and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.
    measure
    Number of Participants With Persistence or Relapse of Malignancy at 2 Years Post Transplant
    time Frame
    2 years
  5. description
    Defined as the return of disease after its apparent recovery/cessation. Patients with leukemia and lymphoma involving the BM and multiple myeloma will have this done by BM biopsy and additional special studies such as cytogenetics or flow cytometry as appropriate. Patients with lymphoma and myeloma will have radiology studies such as plain X-rays or CT scans and/or other studies such as blood tumor markers to document presence or absence of disease as clinically indicated.
    measure
    Number of Participants With Persistence or Relapse of Malignancy at 5 Years Post Transplant
    time Frame
    5 years
  6. description
    The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer.
    measure
    Number of Participants Who Were Alive at 2 Year Post Transplant
    time Frame
    2 years
  7. description
    The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer.
    measure
    Number of Participants Who Were Alive at 5 Year Post Transplant
    time Frame
    5 years
  8. description
    Graft failure is defined as not accepting donated cells. The donated cells do not make the new white blood cells, red blood cells and platelets.
    measure
    Number of Participants Experiencing Engraftment Failure
    time Frame
    Day 42
Full study description
brief Summary
The purpose of this study is to develop a standard of care treatment using allogeneic stem cells for patients with cancers of the blood. The protocol was revised to reflect that this study is considered "treatment guidelines", rather than a research study.
detailed Description
Preparative regimen using total body irradiation (TBI) and cyclophosphamide: 1. on day -6 and -5: cyclophosphamide is given, 2. on day -4, -3, -2, and -1: TBI is given, 3. on day 0: stem cell or bone marrow is infused. Alternate preparative therapy for patients not able to receive TBI The chemotherapy (cyclophosphamide and busulfan) is given with the intent of destroying the bone marrow, eliminating any cancerous and preparing for the transplant of the donor's blood stem cells by suppressing the immune system. l. Ten days before the transplant (Day 10), subjects will be admitted to the bone marrow transplant unit and placed in isolation to reduce exposure to infections. Isolation will be continued until adequate numbers of cells are present in the blood to fight infection. 2\. On day -9, -8, -7, -6 busulfan is given. 3\. On day -5, -4, -3, -2 cyclophosphamide is given. 4\. On day -1 no therapy is given (day of rest). 5\. On day 0 the donor stem cells are given intravenously. Additional cells may be given on day +1 or 2 as needed. Transplant: Subjects will be admitted to the bone marrow transplant unit and put in isolation to reduce exposure to infectious agents. During this time, they will receive the preparative treatment outlined above. Once they have received the preparative regimen, stem cells will be obtained from the donor and given intravenously. The new stem cells will replace the bone marrow that was damaged by the treatment for the cancer. Isolation will be continued until adequate numbers of cells are present in the blood to fight infection. Subjects will then be transferred from the bone marrow transplant unit and discharged from the hospital when medically ready. Subjects will be expected to return for follow-up to the bone marrow transplant clinic at specific dates as determined by their physician.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-b7c17d7eaeff43f37e72
      requested nct id
      NCT00176930
      primary nct id
      NCT00176930
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      ae25242aea6f93c4e840a0df3edd7e8ab4489f6290eca923cb9e6940e659e78c
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-b7c17d7eaeff43f37e72
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00176930
      occurrences
      1. context exact
        NCT00176930
        end
        11
        exact text
        NCT00176930
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/131/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      2959522d866a05073de7e0d0b089824062c9d8a02c31f1fe98ccdf577a9ed5ec

    Preserved source evidence · Not medical advice